The study by Cheng et al(7) provided a detailed evaluation of the lung cancer tumor markers of LUNX, CK19, carcinoembryonic antigen (CEA), vascular endothelial growth factor (VEGF-C) and heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 mRNA and assessed the diagnostic utility of these markers in patients with NSCLC. The gene discussed is BPIFA1; the disease is lung carcinoma.